Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Beth Israel Deaconess Medical Center
Headquarters: Boston, MA, United States of America
Website: http://www.bidmc.org
Year Founded: 1896
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jun 10, 2024
Regulation
Lilly’s Alzheimer’s therapy likely to get similar label to others in amyloid class
Missing or weak data in subgroups should not interfere with approval of donanemab for all patients with early disease, FDA panel concludes
BioCentury | Jan 30, 2024
Emerging Company Profile
NextPoint: a new checkpoint target to extend immunotherapy’s reach
Checkpoint inhibitor against HHLA2-KIR3DL3 axis might work where PD-1 blockers don’t
BioCentury | Dec 23, 2023
Discovery & Translation
Inhaled COVID-19 vaccine; KRAS and GPCR maps and more
BioCentury’s roundup of translational innovations
BioCentury | Sep 27, 2023
Finance
Sept. 26 Quick Takes: Early IgG readout lifts Immunovant
Plus: Acesion raises $48M for atrial fibrillation treatment and updates from A-Alpha, Amgen, Ionis, Pliant, Qihan, Novo, Evotec, ICER, Caribou and AbbVie
BioCentury | Feb 5, 2022
Deals
Feb. 4 Quick Takes: Vanda’s tradipitant records second Phase III miss
Plus: What, me worry? Arcellx goes public amid downdraft; and updates from Regio, J&J, Sanofi, PrecisionLife
BioCentury | Jun 5, 2021
Translation in Brief
Wave provides POC for RNA editing platform; plus Surrozen, Pinteon and Minoryx
BioCentury’s roundup of translational news
BioCentury | Dec 8, 2020
Targets & Mechanisms
Primate study reveals relationship between neutralizing antibodies and T cell responses
A rhesus macaque study argues that CD8+ T cells contribute to immunity against COVID-19, while simultaneously suggesting that antiviral antibodies alone, if at a high enough titer, can protect against
BioCentury | Nov 7, 2020
Targets & Mechanisms
Product profiles that could make interferons effective against COVID-19
Whether interferons live up to their potential as COVID-19 countermeasures may lie in delivery route, tissue specificity
BioCentury | Oct 9, 2020
Translation in Brief
Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine
BioCentury’s roundup of translational news
BioCentury | Jul 31, 2020
Product Development
Non-human primate data shed light on correlates of protection and duration of immunity to COVID-19 vaccines
Items per page:
1 - 10 of 196